RT Journal Article SR Electronic T1 "Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease" JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P722 VO 44 IS Suppl 58 A1 Shashank Sharma A1 Winston Banya A1 Elizabeth Renzoni A1 Athol Wells A1 Maher Toby YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P722.abstract AB Aim:Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders with different histological subtypes, pathobiology, prognosis and response to treatment. There is paucity of randomised controlled trials to guide treatment in majority of ILDs, however, cyclophosphamide is widely used in the treatment of inflammatory driven ILD. We sought to retrospectively assess treatment response to cyclophosphamide in our cohort of ILD patients. Method: Using electronic medical records and our pharmacy database we identified all patients treated with at least one dose of cyclophosphamide between January 2010 and December 2011. Only patients with lung function data available from at least 6 months prior to treatment through to 6 months after completion of cyclophosphamide were included in analyses.Results: A total of 192 electronic patient records were screened and 100 patients were excluded due to incomplete data. Patient characteristics are shown in table 1. There was a significant change in the ΔFVC when comparing the 6 month period before (-5.13% ± S.D. 1.0186 %) and the six month period after (-1.45% ± S.D. 0.8583) treatment with cyclophosphamide (p = 0.0133). . Similarly ΔDlCO also improved from -5.75% ± S.D. 07864 to -1.33% ± S.D. 0.6537 (p = 0.0002).Conclusion: Monthly intravenous cyclophosphamide, is a safe and effective treatment in an unselected group of patients with inflammation driven fibrotic ILD.View this table:Patient characterstics.